Panagora Asset Management Inc. Acquires New Position in Medpace Holdings, Inc. $MEDP

Panagora Asset Management Inc. acquired a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) in the fourth quarter, HoldingsChannel reports. The institutional investor acquired 54,664 shares of the company’s stock, valued at approximately $30,702,000.

A number of other hedge funds also recently made changes to their positions in MEDP. AQR Capital Management LLC grew its stake in shares of Medpace by 65.1% during the 3rd quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock valued at $518,170,000 after acquiring an additional 404,226 shares during the period. Arrowstreet Capital Limited Partnership grew its stake in shares of Medpace by 205.8% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock valued at $161,523,000 after acquiring an additional 211,411 shares during the period. Franklin Resources Inc. grew its stake in shares of Medpace by 158.6% during the 4th quarter. Franklin Resources Inc. now owns 299,472 shares of the company’s stock valued at $168,198,000 after acquiring an additional 183,645 shares during the period. Norges Bank bought a new position in shares of Medpace during the 4th quarter valued at approximately $102,156,000. Finally, Goldman Sachs Group Inc. grew its stake in shares of Medpace by 92.4% during the 4th quarter. Goldman Sachs Group Inc. now owns 347,049 shares of the company’s stock valued at $194,920,000 after acquiring an additional 166,654 shares during the period. 77.98% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have weighed in on MEDP. BMO Capital Markets dropped their price target on Medpace from $460.00 to $400.00 and set a “market perform” rating for the company in a research note on Friday, April 24th. Wall Street Zen downgraded Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. TD Cowen upgraded Medpace from a “sell” rating to a “hold” rating and dropped their price target for the stock from $462.00 to $419.00 in a research note on Wednesday, February 18th. Weiss Ratings downgraded Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, April 6th. Finally, Robert W. Baird dropped their price target on Medpace from $565.00 to $477.00 and set an “outperform” rating for the company in a research note on Friday, April 24th. Four analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Medpace has an average rating of “Hold” and a consensus target price of $467.08.

Insider Activity

In other news, General Counsel Stephen P. Ewald sold 16,349 shares of the company’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the sale, the general counsel directly owned 20,343 shares of the company’s stock, valued at $9,154,350. This represents a 44.56% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 20.50% of the stock is owned by company insiders.

Medpace Price Performance

MEDP stock opened at $467.50 on Tuesday. Medpace Holdings, Inc. has a 1-year low of $294.07 and a 1-year high of $628.92. The company has a market capitalization of $13.35 billion, a price-to-earnings ratio of 29.38, a PEG ratio of 2.37 and a beta of 1.18. The business has a 50 day simple moving average of $455.81 and a two-hundred day simple moving average of $502.82.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, topping the consensus estimate of $3.74 by $0.54. The business had revenue of $706.60 million during the quarter, compared to the consensus estimate of $697.82 million. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The firm’s revenue for the quarter was up 26.5% compared to the same quarter last year. During the same period in the prior year, the company posted $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Sell-side analysts anticipate that Medpace Holdings, Inc. will post 17.04 EPS for the current fiscal year.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.